Liquidia Corp (NASDAQ: LQDA) saw insider activity on April 27, 2026, as Chief Accounting Officer Dana Boyle executed a sale of company shares. The transaction involved the disposal of 1,576 shares of common stock at a price point of $37.78 per share, resulting in total proceeds of $59,541.
The divestment was not an ad hoc decision but rather followed a Rule 10b5-1 trading plan that Ms. Boyle had adopted on December 15, 2023. According to regulatory filings, the purpose of this specific sale was to facilitate the settlement of taxes associated with restricted stock units (RSUs) that were first granted to her on January 25, 2023.
Following the completion of this transaction, Ms. Boyle's direct ownership in Liquidia common stock stands at 175,342 shares. This remaining stake is composed of various elements, including unvested restricted stock units issued between January 2023 and January 2026, alongside shares acquired through the Liquidia Corporation 2020 Employee Stock Purchase Plan.
Market Context and Performance
The sale occurred against a backdrop of significant upward momentum for Liquidia's stock. The company's shares have seen a notable rise, climbing 183% over the previous year and experiencing a 70% surge within the last six months. As of the latest data, the stock was trading at $38.15.
Liquidia's recent financial trajectory is heavily influenced by the performance of its Yutrepia drug. In the fourth quarter of 2025, the company reported revenue of $90.1 million from Yutrepia, which represented a 74% increase on a quarter-over-quarter basis. Looking further ahead, Liquidia has provided revenue guidance that anticipates exceeding the $1 billion mark by 2027.
Key Insights
- Strategic Product Growth: The rapid revenue expansion of Yutrepia, growing 74% quarter-over-quarter, serves as a primary driver for the company's current valuation and market position in the prostacyclin treatment space.
- Institutional Optimism: Major financial institutions have signaled confidence in the company's direction. H.C. Wainwright has set a price target of $55 with a Buy rating, while BTIG raised its target to $50 based on Yutrepia's launch performance. Raymond James maintains a Strong Buy with a $47 target, and BofA Securities holds a Buy rating with a $44 target.
- Valuation Discrepancies: Despite the stock's recent gains, some analyses suggest that Liquidia may currently be undervalued relative to Fair Value estimates for its $3.36 billion market cap.
Risks and Uncertainties
- Earnings Volatility: While revenue from Yutrepia showed strong growth in Q4 2025, the company's earnings per share (EPS) failed to meet expectations, highlighting a potential gap between top-line revenue success and bottom-line profitability.
- Execution of Long-term Guidance: The company has set an ambitious revenue target exceeding $1 billion for 2027; meeting this milestone remains a critical variable for long-term investor confidence.